Abstract
As in other countries, Pharmacovigilance (PMS) in France demands frequent relations between Industry and Health Authorities. Out of the purely legal-based relationships it has been possible to reach a more contractual attitude based on three particularities of the system:
Official designation in each company of an individual nominally responsible for pharmacovigilance. Official presence of an Industry representative on the National Pharmacovigilance Committee. Constitution of a mixed group of academic and industrial specialists on the national level.
These relations do not hinder Health Authorities, whose decisions remain totally independent.
Get full access to this article
View all access options for this article.